A literature review of the patent publications on venetoclax – a selective Bcl-2 inhibitor: discovering the therapeutic potential of a novel chemotherapeutic agent

References

• World Health Organization [Internet]. World Health Organization; [cited 2018 Jul 25]. Available from: http://www.who.int/cancer/en/.
   Google Scholar
• World Cancer Research Fund International [Internet]. [cited 2018 Jul 25]. Available from: https://www.wcrf.org/int/cancer-facts-figures/worldwide-data.
   Google Scholar
• Cancer Research UK [Internet]. [cited 2018 Jul 25]. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/leukaemia.
   Google Scholar
• Cancer Research UK [Internet]. [cited 2018 Jul 25]. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/hodgkin-lymphoma.
   Google Scholar
• Cancer Research UK [Internet]. [cited 2018 Jul 25]. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/non-hodgkin-lymphoma.
   Google Scholar
• Lichtman MA. Battling the Hematological Malignancies: the 200 Years’ War. Oncologist. 2008;13:126–138.
   PubMed Web of Science ®Google Scholar
• Drugs.com. Venclexta Approval History [Internet]; 2019 [cited 2019 May 21]. Available from: https://www.drugs.com/history/venclexta.html.
   Google Scholar
• U.S. Food & Drug Administration. Search orphan drug designations and approvals; Venetoclax [Internet]. [cited 2019 May 21]. Available from: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=600117.
   Google Scholar
• European Medicines Agency. Venclyxto (venetoclax) EPAR: An overview of Venclyxto and why it is authorised in the EU; 2018.
   Google Scholar
• Tsujimoto Y, Finger LR, Yunis J, et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science. 1984;226:1097–1099.
   PubMed Web of Science ®Google Scholar
• Mullard A. Pioneering apoptosis-targeted cancer drug poised for FDA approval. Nat Rev Drug Discov. 2016;15:147–149.
   PubMed Web of Science ®Google Scholar
• Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide- ranging implications in tissue kinetics. Br J Cancer. 1972;26:239–257.
   PubMed Web of Science ®Google Scholar
• Petch A, Al-Rubeai M. The Bcl-2 family. Cell Eng. 2004: 25–47.
   Google Scholar
• Delbridge ARD, Strasser A. The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ. 2015;22:1071–1080.
   PubMed Web of Science ®Google Scholar
• Montero J, Letai A. Why do BCL-2 inhibitors work and where should we use them in the clinic? Cell Death Differ. 2018;25:56–64.
   PubMed Web of Science ®Google Scholar
• Kalkavan H, Green DR. MOMP, cell suicide as a BCL-2 family business. Cell Death Differ. 2018;25:46–55.
   PubMed Web of Science ®Google Scholar
• Opferman JT, Kothari A. Anti-apoptotic BCL-2 family members in development. Cell Death Differ. 2018;25:37–45.
   PubMed Web of Science ®Google Scholar
• Kale J, Osterlund EJ, Andrews DW. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 2018;25:65–80.
   PubMed Web of Science ®Google Scholar
• Adams JM, Cory S. The BCL-2 arbiters of apoptosis and their growing role as cancer targets. Cell Death Differ. 2018;25:27–36.
   PubMed Web of Science ®Google Scholar
• Yap JL, Chen L, Lanning ME, et al. Expanding the cancer arsenal with targeted therapies: disarmament of the antiapoptotic Bcl-2 proteins by small molecules. J Med Chem. 2017;60:821–838.
   PubMed Web of Science ®Google Scholar
• Ku B, Liang C, Jung JU, et al. Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX. Cell Res. 2011;21:627–641.
   PubMed Web of Science ®Google Scholar
• Reed JC. Bcl-2 on the brink of breakthroughs in cancer treatment. Cell Death Differ. 2018;25:3–6.
   PubMed Web of Science ®Google Scholar
• Beauparlant P, Shore GC. Therapeutic small molecule inhibitors of bcl-2. Cell Eng. 2004; 223–237.
   Google Scholar
• Miyashita T, Reed JC. Bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res. 1992;52:5407–5411.
   PubMed Web of Science ®Google Scholar
• Manion MK, Fry J, Schwartz PS, et al. Small molecule inhibitors of Bcl-2. Curr Opin Investig Drugs. 2006;7:1077–1084.
   PubMed Web of Science ®Google Scholar
• Zhu H, Almasan A. Development of venetoclax for therapy of lymphoid malignancies. Drug Des Devel Ther. 2017;11:685–694.
   PubMed Web of Science ®Google Scholar
• Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435:677–681.
   PubMed Web of Science ®Google Scholar
• Del Gaizo Moore V, Schlis KD, Sallan SE, et al. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood. 2008;111:2300–2309.
   PubMed Web of Science ®Google Scholar
• Tse C, Shoemaker AR, Adickes J, et al. ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68:3421–3428.
   PubMed Web of Science ®Google Scholar
• Wilson WH, O’Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11:1149–1159.
   PubMed Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–208.
   PubMed Web of Science ®Google Scholar
• Davids MS, Letai A. ABT-199: taking dead aim at BCL-2. Cancer Cell. 2013;23:139–141.
   PubMed Web of Science ®Google Scholar
• King AC, Peterson TJ, Horvat TZ, et al. Venetoclax: A First-in-class oral BCL-2 inhibitor for the management of lymphoid malignancies. Ann Pharmacother. 2017;51:410–416.
   PubMed Web of Science ®Google Scholar
• Liu X, Zhang Y, Huang W, et al. Design, synthesis and pharmacological evaluation of new acyl sulfonamides as potent and selective Bcl-2 inhibitors. Bioorg Med Chem. 2018;26:443–454.
   PubMed Web of Science ®Google Scholar
• Vogler M, Dinsdale D, Dyer MJS, et al. ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. Br J Haematol. 2013;163:139–142.
   PubMed Web of Science ®Google Scholar
• Mihalyova J, Jelinek T, Growkova K, et al. Venetoclax: a new wave in hematooncology. Exp Hematol. 2018;61:10–25.
   PubMed Web of Science ®Google Scholar
• Bruncko M, Ding H, Doherty G, et al. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases. WO 2010/138588 A2. 2010.
   Google Scholar
• Bruncko M, Ding H, Doherty G, et al. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases. WO 2011/149492 A1. 2011.
   Google Scholar
• Elmore S, Souers A, Wang LC, et al. Methods of treatment using selective BCL-2 inhibitors. WO 2012/071374 A1. 2012.
   Google Scholar
• Catron ND, Chen S, Gong Y, et al. Salts and crystalline forms of an apoptosis-inducing agent. WO 2012/071336 A1. 2012.
   Google Scholar
• Barkalow J, Califano J-C, Chan VS, et al. Processes for the preparation of an apoptosis-inducing agent. WO 2014/165044 A1. 2014.
   Google Scholar
• Ge M, Xu YL. [Synthesis of Bcl-2 inhibitor ABT-199]. CN 104370905 B. 2016.
   Google Scholar
• Hughes DL. Patent review of manufacturing routes to oncology drugs: carfilzomib, osimertinib, and venetoclax. Org Process Res Dev. 2016;20:2028–2042.
   Google Scholar
• Birtalan E, Hoelig P, Lindley DJ, et al. Melt-extruded solid dispersions containing an apoptosis-inducing agent. WO 2012/121758 A1. 2012.
   Google Scholar
• Catron ND, Lindley DJ, Miller J, et al. Solid dispersions containing an apoptosis-inducing agent. WO 2012/058392 A1. 2012.
   Google Scholar
• Bruncko M, Ding H, George DA, et al. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases. US 9,174,982 B2. 2015.
   Google Scholar
• Bruncko M, Ding H, Doherty G, et al. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases. EP 2 435 432 B1. 2015.
   Google Scholar
• Bruncko M, Ding H, Doherty G, et al. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases. EP 2 576 546 B1. 2015.
   Google Scholar
• Bernstein BE, Aster JC, Bradner JE, et al. Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy. WO 2013/192274 A9. 2013.
   Google Scholar
• Bernstein BE, Aster JC, Bradner JE, et al. Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy. US 9,763,956 B2. 2017.
   Google Scholar
• Eastman AR, Bates D. Method for treating chronic lymphocytic leukemia. WO 2015/149105 A1. 2015.
   Google Scholar
• Strack P, Booher R. Method for treating cancer. WO 2015/130585 A1. 2015.
   Google Scholar
• Strack P, Booher R. Method for treating cancer. US 9,925,192 B2. 2018.
   Google Scholar
• He W. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases. WO 2017/218844 A2. 2017.
   Google Scholar
• Starczynowski D, Rhyasen GW. Combination therapy for MDS. WO 2014/190163 A2. 2014.
   Google Scholar
• Starczynowski D, Rhyasen GW. Combination therapy for MDS. US 9,504,706 B2. 2016.
   Google Scholar
• Starczynowski D, Rhyasen GW. Combination therapy for MDS. US 9,168,257 B2. 2015.
   Google Scholar
• Starczynowski D, Rhyasen GW. Combination therapy for MDS. EP 2 999 470 B1. 2017.
   Google Scholar
• Starczynowski D, Rhyasen GW. Combination therapy for MDS. US 9,855,273 B2. 2018.
   Google Scholar
• Stern HM, Kutok JL. Treatment of cancers using PI3 kinase isoform modulators. WO 2014/071109 A1. 2014.
   Google Scholar
• Walensky LD. Inhibition of MCL-1 and/or BFL-1/A1. WO 2013/142281 A1. 2013.
   Google Scholar
• Walensky LD. Inhibition of MCL-1 and/or BFL-1/A1. US 9,926,306 B2. 2018.
   Google Scholar
• Walensky LD. Inhibition of MCL-1 and/or BFL-1/A1. AU 2013235425 B2. 2017.
   Google Scholar
• Hill O, Gieffers C, Thiemall M, et al. Single-chain TRAIL-receptor agonist proteins. WO 2015/164588 A1. 2015.
   Google Scholar
• Marchini A, Li J, Schroeder L, et al. Cancer therapy with a parvovirus combined with a BCL-2 inhibitor. WO 2015/010782 A1. 2015.
   Google Scholar
• Marchini A, Li J, Schroeder L, et al. Cancer therapy with a parvovirus combined with a Bcl-2 inhibitor. US 9,889,169 B2. 2018.
   Google Scholar
• Marchini A, Li J, Schroeder L, et al. Cancer therapy with a parvovirus combined with a Bcl-2 inhibitor. EP 3 024 491 B1. 2017.
   Google Scholar
• Marchini A, Li J, Schroeder L, et al. Cancer therapy with a parvovirus combined with a Bcl-2 inhibitor. JP 6195988 B2. 2017.
   Google Scholar
• Marchini A, Li J, Schroeder L, et al. Cancer therapy with a parvovirus combined with a Bcl-2 inhibitor. AU 2014295442 B2. 2017.
   Google Scholar
• Crawford J, Wei B, Young WB. Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality. WO 2015/082583 A1. 2014.
   Google Scholar
• Link AJ, Zhang S. Novel engineered potent cytotoxic stapled BH3 peptides. WO 2013/116829 A1. 2013.
   Google Scholar
• Link AJ, Zhang S. Engineered potent cytotoxic stapled BH3 peptides. US 9,464,125 B2. 2016.
   Google Scholar
• Reilly EB, Phillips AC, Benatuil L, et al. Anti-EGFR antibodies and antibody drug conjugates. WO 2015/143382 A1. 2015.
   Google Scholar
• Bialucha CU, Collins S, Hu T, et al. Anti-CDH6 antibody drug conjugates. WO 2016/024195 A1. 2016.
   Google Scholar
• Sun LL, Chen YM-Y, Dennis MS, et al. Anti-CD79b antibodies and methods of use. WO 2016/090210 A1. 2016.
   Google Scholar
• Walsh K, de Almeida P, Du C, et al. Combination therapy comprising anti-angiogenesis agent and OX40 binding antibodies. WO 2015/153514 A1. 2015.
   Google Scholar
• Du C, Kim J, Zhu J, et al. Anti-OX40 antibodies and methods of use. WO 2015/153513 A1. 2015.
   Google Scholar
• Madhok R. Systemic lupus erythematosus: lupus nephritis. BMJ Clin Evid. 2015;12:1123.
   Google Scholar
• Mavragani CP, Moutsopoulos HM. Sjögren syndrome. Cmaj. 2014;186:579–586.
   PubMed Web of Science ®Google Scholar
• Laberge R-M, Campisi J, Davalos A, et al. Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders. WO 2015/116740 A1. 2015.
   Google Scholar
• Collado M, Blasco MA, Serrano M. Cellular Senescence in Cancer and Aging. Cell. 2007;130:223–233.
   PubMed Web of Science ®Google Scholar
• Yosef R, Pilpel N, Tokarsky-Amiel R, et al. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat Commun. 2016;7:11190.
   PubMed Web of Science ®Google Scholar
• Delbridge ARD, Grabow S, Strasser A, et al. Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat Rev Cancer. 2016;16:99–109.
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Fairbrother WJ, Leverson JD, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat Rev Drug Discov. 2017;16:273–284.
   PubMed Web of Science ®Google Scholar
• U.S. National Library of medicine. ClinicalTrials.gov [Internet]. [cited 2019 May 23]. Available from: https://clinicaltrials.gov/ct2/home.
   Google Scholar
• Bhushan A. Inhibiting senescent processes in beta cells for the prevention of type 1 diabetes. WO 2018/204830 A2. 2018.
   Google Scholar
• Li F, Li R, Ling D, et al. [Preparation method of pH-sensitive nano Bcl-2 selective inhibitor and product and application]. CN 106822916 A. 2017.
   Google Scholar
• Yuan S, Chan FWJ, Yuen KY, et al. Zika virus protease inhibitors and methods of use thereof. WO 2018/192083 A1. 2018.
   Google Scholar
• Madej T, Lanczycki CJ, Zhang D, et al. MMDB and VAST+: tracking structural similarities between macromolecular complexes. Nucleic Acids Res. 2014;42:297–303.
   Web of Science ®Google Scholar
• iCn3D. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information. 2016. [Internet]. Available from: https://www.ncbi.nlm.nih.gov/Structure/icn3d/icn3d.html
   Google Scholar
• Coleman P, Huang D, Lessene G, et al. Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. Nat Commun. 2019;10:2385.
   Web of Science ®Google Scholar